Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
Theriva Biologics, Inc., a Nevada corporation, filed this Current Report on Form 8-K on August 11, 2025. The filing serves to announce the issuance of a press release containing financial information for the quarter ended June 30, 2025. The company is listed on the NYSE American under the symbol TOVX and is designated as an emerging growth company.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that such data is available in the attached press release (Exhibit 99.1), which is incorporated by reference but not included in the text provided for analysis.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The filing explicitly states that the financial details are contained within the referenced press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. No specific guidance, outlook, or risk factors are enumerated in the text of this report.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 11, 2025) for actual financial figures for the quarter ended June 30, 2025.
- Verify the company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (TOVX) and exchange (NYSE American) for accurate market data retrieval.
- Note that the financial data in the press release is not considered "filed" under Section 18 of the Exchange Act.